Endoxan: Side Effects & Dosing

Indications/Uses

Chemotherapy of malignant tumors & leukemia.

Dosage/Direction for Use

Initial treatment Daily IV inj of 3-6 mg/kg (120-240 mg/m²) or 10-15 mg/kg (400-600 mg/m²) w/ therapy-free intervals of 2-5 days; or 20-40 mg/kg body wt w/ therapy-free intervals of 10-20 days. Maintenance 50-200 mg/day orally.

Administration

Should be taken on an empty stomach: Best taken on an empty stomach. May be taken w/ meals to minimise GI irritation. Ensure adequate fluid intake. Swallow whole.

Contraindications

Severe bone marrow suppression, severe impairment of renal function, lower urinary outflow obstruction, acute infection. Pregnancy.

Special Precautions

Patients of reproductive age should use contraceptives throughout therapy & for not <6 mth afterwards. DM. Renal & hepatic failure. Elderly & debilitated patients.

Adverse Reactions

GI upsets; alopecia; reticulo-endothelial system depression; hematuria; reversible amenorrhea & azoospermia; myocardial damage w/ very high doses; pigmentation, macrocytosis, water retention; induction of hyperglycemia or hypoglycemia; risk of secondary malignancies.

View ADR Reporting Link

Drug Interactions

May potentiate hypoglycemic effect of sulfonylureas. Allopurinol (increased incidence of bone marrow depression). Suxamethonium (prolongation of apnoea).

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01AA01 - cyclophosphamide ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer.

Thai FDA Category

S

Presentation/Packing

Form

Endoxan coated tab 50 mg

Packing/Price

200's

Form

Endoxan powd for inj 1000 mg

Packing/Price

1's

Form

Endoxan powd for inj 500 mg

Packing/Price

1's

Endoxan

cyclophosphamide

Manufacturer:

Baxter International

Distributor:

Zuellig Pharma